Previously dba as REBIScan, Rebio is organized around development of a diagnostic tool designed to detect and eradicate vision loss in children. Anchored in work originally undertakenby one of the Founders at Johns Hopkins, the company's Neural Performance Scanning (NPS) technology and data management tools provide a faster, more efficient and safer way to scan people, making early intervention and treatment more widely accessible than ever before. The assembled team - drawn from a range of leading instiutions in the field - is building transformative technology that accurately and instantaneously detects vision disorders for timely referral and treatment. The first device, the Pediatric Vision Scanner (PVS), detects amblyopia, the leading cause of vision loss in children. A 3-second scan performed by a non-clinician using the PVS replaces the 5-10 minute clinician examination currently required to detect disease, and it does so with unprecedented accuracy. Rebion's Neural Performance Scanning (NPS) technology and data management tools provide a faster, more efficient and safer way to scan people, making early intervention and treatment more widely accessible than ever before. The firm has developed a diagnostic tool designed to detect and eradicate vision loss in children. Rebions Head & Intraocular Trauma Test (HITT) leverages Neural Performance Scanning to detect and monitor brain impairment related to traumatic brain injury. HITT is both an entry gate as part of an effective diagnosis protocol, as well as an exit gate to assess progress and treatment. Many life-altering diseases such as lazy eye and TBI are associated with impaired brain function, and because there are so many barriers to early detection, they often go undiagnosed and untreated at critical stages where early intervention can reduce life-long hardship for those affected. Rebions Neural Performance Scanning (NPS) makes wide-scale, early intervention feasible by definitively detecting impaired brain function, fast and effectively. using a portable low-power laser to scan retinal nerve fibers, NPS precisely measures signal patterns that return from the brain, instantly determining if faulty signal processing is present. Patients can be confidently referred for further diagnosis and treatment, improving health outcomes and reducing treatment costs. This proprietary technology is cleared for use by the FDA and is certifed for use by medical professionals and lay users alike, allowing for deployment when and where its needed.
